<unk>  is a CD19-directed genetically modified autologous T-cell immunotherapy that is FDA approved for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse and adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include cytokine release syndrome, hypogammaglobulinemia, infections-pathogen unspecified, pyrexia, decreased appetite, headache, encephalopathy, hypotension, bleeding episodes, tachycardia, nausea, diarrhea, vomiting, viral infectious disorders, hypoxia, fatigue, acute kidney injury, edema, cough, delirium.
Tisagenlecleucel
Ecallantide
Crofelemer
Ciclopirox
Picloxydine
Xaliproden
Prothipendyl
Iproclozide